摘要
慢性阻塞性肺疾病(慢阻肺)全球创议(global initiative for chronic obstructive lung disease,GOLD)2019年修订版于2018年11月7日发布,相较于GOLD 2018,GOLD 2019最重要的改变是在慢阻肺稳定期章节增加了慢阻肺初始药物治疗方案和随访期药物调整策略,并强调了血嗜酸粒细胞作为慢阻肺患者吸入激素获益的生物标志物。本文对新增加内容进行介绍和解读。
Global initiative for chronic obstructive lung disease(GOLD)2019 report was released on Nov 7,2018.The GOLD 2019 report is a minor revision of the GOLD 2017 report.This article mainly focus on interpreting updates of management cycle including initial pharmacological treatment and follow-up pharmacological treatment and the role of blood eosinophils in predicting inhaled corticosteroid effect in GOLD 2019 report.
作者
陈亚红
CHEN Ya-hong(Department of Respiratory and Critical Care Medicine,Peking University Third Hospital,Beijing 100191,China)
出处
《中国医学前沿杂志（电子版）》
2019年第1期1-14,共14页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家重点研发计划"重大慢性非传染性疾病防控研究"专项课题(2016YFC1304301)
精准医学研究专项(2016YFC0903601
2016YFC0901102)
关键词
慢性阻塞性肺疾病
症状
急性加重
嗜酸粒细胞
个体化治疗
Chronic obstructive pulmonary disease
Symptom
Acute exacerbation
Eosinophils
Individualized treatment
